— Know what they know.
Not Investment Advice

VTYX NASDAQ

Ventyx Biosciences, Inc.
1W: +0.2% 1M: +0.7% 3M: +78.6% YTD: +66.7% 1Y: +821.0% 3Y: -68.5%
$14.00
Last traded 2026-03-06 — delisted
NASDAQ · Healthcare · Biotechnology · $1.0B mcap · 48M float · 7.97% daily turnover · Short 50% of daily vol

Balance Sheet Trends

Total Assets
$277M -0.4% ▼
5Y CAGR: +280.0%
Total Liabilities
$23M -33.3% ▼
5Y CAGR: +38.1%
Shareholders Equity
$254M +4.1% ▲
Cash & Investments
$217M -13.8% ▼
5Y CAGR: +271.0%
Total Debt
$11M -13.7% ▼
5Y CAGR: +22.9%
Net Debt
-$16M +57.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$244K$71M$65M$52M$27M
Short-Term Investments$0$188M$253M$201M$190M
Cash & ST Investments$244K$259M$318M$252M$217M
Net Receivables$0$0$0$0$1M
Inventory$0$0$0$0$0
Other Current Assets$0$0$13M$12M$11M
Total Current Assets$245K$263M$331M$264M$230M
Property, Plant & Equip.$0$254K$2M$12M$10M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$28M$39M$0$36M
Other Non-Current Assets$0$60K$96K$1M$1M
Total Non-Current Assets$0$28M$41M$13M$47M
Total Assets$245K$291M$371M$278M$277M
— Liabilities —
Accounts Payable$1M$5M$6M$6M$3M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$0$0$0
Total Current Liabilities$1M$12M$16M$22M$13M
Long-Term Debt$13M$0$0$0$0
Other Non-Current Liab.$17M$0$0$0$0
Total Non-Current Liabilities$29M$0$1M$12M$10M
Total Liabilities$31M$12M$18M$34M$23M
— Equity —
Common Stock$0$5K$6K$6K$7K
Retained Earnings-$33M-$118M-$226M-$419M-$554M
Accumulated OCI$0-$58K-$1M-$50K$157K
Total Stockholders Equity-$31M$279M$354M$244M$254M
Total Liabilities & Equity$245K$291M$371M$278M$277M
— Key Metrics —
Total Debt$13M$0$2M$13M$11M
Net Debt$12M-$71M-$63M-$39M-$16M
Total Investments$0$216M$292M$201M$226M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms